医学
尿路上皮癌
血液透析
尿路上皮癌
内科学
肿瘤科
转移性尿路上皮癌
泌尿科
癌症
膀胱癌
作者
Harshit Khosla,S. T. Bhatt,Ming-Jin Wang,Gretchen A. Gignac,Kriti Mittal,Jasmine Patel
标识
DOI:10.1177/10781552241237752
摘要
Enfortumab vedotin (EV) is a novel treatment option for patients with advanced/metastatic urothelial carcinoma who have progressed after chemotherapy and immunotherapy. Two patients at two different New England tertiary cancer care centers were treated with EV while concurrently receiving hemodialysis (HD), where a complete response to EV in both patients was noted. The use of EV in patients requiring HD is extrapolated from the available pharmacokinetic and pharmacodynamic literature on monoclonal antibodies in patients requiring HD. There is a paucity of data for the use of antibody-drug conjugates like EV in patients needing dialysis.
科研通智能强力驱动
Strongly Powered by AbleSci AI